Oncology · BiosimilarRegulatory Approvalregulatorymid-term

FDA Accepts Supplement Application for ONTRUZANT (Trastuzumab-DTTB)

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/4/2026, 12:33:21 AM

Assessment confidence: 61% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The FDA's acceptance of the supplemental application for ONTRUZANT is a significant regulatory milestone that could strengthen Samsung Bioepis's competitive position in the oncology biosimilar market. This development necessitates close monitoring of market dynamics and potential pricing strategies among trastuzumab products. Regulatory context from FDA (FDA AP — ONTRUZANT (SUPPL)) supports the near-term read. Assessment grounded in 25 ranked evidence items (8 high-relevance).

Strategic Assessment

Portfolio teams should assess the potential impact on market share and pricing strategies in the biosimilar segment. The strongest clinical anchor is HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer (ClinicalTrials.gov), entity match (trastuzumab). In Oncology · Biosimilar, 6 regulatory and 4 competitive items passed relevance filtering for ONTRUZANT.

Competitive Pressure

The most relevant competitive pressure comes from FDA Accepts Supplemental Application for KEYTRUDA QLEX (Humanexa Signals) — sponsor/company relevance (merck). Secondary pressure from FDA Approves Supplemental Application for SARCLISA (Isatuximab-IRFC). This acceptance may enhance Samsung Bioepis's position in the oncology biosimilar market, particularly against established trastuzumab products.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — ONTRUZANT (SUPPL) (FDA). Entity match (ontruzant). While the acceptance indicates progress, the final FDA decision will ultimately determine the product's market entry and compliance requirements.

Key Risks

Elevated medium regulatory exposure for ONTRUZANT could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The acceptance may lead to increased market share for ONTRUZANT, impacting revenue projections for both Samsung Bioepis and existing trastuzumab products.
Upside for ONTRUZANT may improve if HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer (ClinicalTrials.gov) delivers favorable follow-through.
Lead sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest. Collaborators: Merck Sharp & Dohme LLC, Organon Healthcare GmbH.
Oncology · PD-1 Inhibitor · Regulatory Approval · This acceptance may enhance Merck's competitive positioning in the oncology market, particularly in combination therapies.
Upside for ONTRUZANT may improve if Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP. (PubMed) delivers favorable follow-through.

What Would Change This Assessment

This becomes more urgent if Monitor the timeline for the FDA's final decision and any competitive responses from other trastuzumab manufacturers.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — ONTRUZANT (SUPPL)
FDAhigh relevance
Entity match (ontruzant)
FDA document
View source
FDA AP — ONTRUZANT (SUPPL)
FDAhigh relevance
Entity match (ontruzant)
FDA document
View source
FDA AP — ENHERTU (SUPPL)
FDAhigh relevance
Entity match (trastuzumab)
FDA document
View source
IND Application Reporting: IND Safety Reports
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Investigational New Drug (IND) Application
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer
ClinicalTrials.govhigh relevance
Entity match (trastuzumab)
FDA document
View source
Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma
ClinicalTrials.govhigh relevance
Entity match (trastuzumab)
FDA document
View source
Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer
ClinicalTrials.govhigh relevance
Entity match (trastuzumab)
FDA document
View source
Pomegranate Dietary Supplements in AUD and ALD
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Oral Nutritional Supplement in Adults With or at Risk of Malnutrition
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Effect of Foot Massage on Pain and Analgesic Consumption in Total Knee Prosthesis
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Accepts Supplemental Application for KEYTRUDA QLEX
Humanexa Signalshigh relevance
Sponsor/company relevance (Merck)
FDA Approves Supplemental Application for SARCLISA (Isatuximab-IRFC)
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Approves Supplemental Applications for TRELSTAR
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Accepts Supplemental Application for TRYNGOLZA Autoinjector
Humanexa Signalsmedium relevance
Moderate corpus alignment

A 3.6:1 myo-inositol to D-chiro-inositol ratio and antioxidant-based food supplement before IVF improves fertility in women with PCOS: a pilot observational retrospective cohort study.
PubMedhigh relevance
Mechanism alignment (IO )
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Selected immunoendocrine and performance adaptations to upper-body plyometric training and β-alanine supplementation in male swimmers.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of carnosine supplementation on physical endurance: a placebo-controlled randomized clinical trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
The application of growth factors in bone tissue engineering delivery systems and collaborative innovation strategies.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Type 2 diabetes remission in gynaecologic oncology patients completing an acute preoperative weight loss protocol: a case series.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

ONTRUZANT
trastuzumab

Commercial impact

medium

The acceptance may lead to increased market share for ONTRUZANT, impacting revenue projections for both Samsung Bioepis and existing trastuzumab products.

Regulatory impact

medium

While the acceptance indicates progress, the final FDA decision will ultimately determine the product's market entry and compliance requirements.

What to watch

Monitor the timeline for the FDA's final decision and any competitive responses from other trastuzumab manufacturers.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.